

PreserveRxSM at a glance:

What is PreserveRxSM?

It's financial protection for health plans that helps preserve patient access to innovative gene therapies.

What advantages does PreserveRx offer?

PreserveRx helps health plans and employers reduce financial risk in a changing gene therapy market.



Robust forecasting, underwriting and cost impact analysis



Detailed data and advanced expertise to make sure members get the right treatment



Enhanced access, outcomes tracking and reporting

How does it differ from other gene therapy financial protection?

PreserveRx covers up to **5** high-cost gene therapies currently on the market, or expected to be on the market, by end of 2020.

This is more than any other available gene therapy financial protection. As new gene therapies are approved, it will cover even more.

Currently in market

Luxturna[®] Zolgensma[®]


Expected additions to market in 2020

Valrox GT-AADC
LentiGlobin[®]


Why is PreserveRx so important now?

The number of gene therapies for rare conditions are growing. So are the costs. An estimated 60 gene therapies will come to market in the next 10 years.

\$72B




\$2B



Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. Value in Health, Volume 22, Issue 6, 621-626.

EXAMPLE

For a member receiving Zolgensma, the financial protection with PreserveRx is clear.



*Payer obligation following any patient responsibility or any stop loss coverage is applied.

**Provider cost markup above WAC, if applicable.